6-Mercaptopurine (6-MP) is metabolized by thiopurine Smethyltransferase (TPMT), an enzyme subject to genetic polymorphism. We investigated the relationships between the TPMT locus (TPMT activity and genotype) and the pharmacological response to 6-MP during maintenance therapy of 78 children with acute lymphoblastic leukemia (ALL). For each patient, 6-MP dosage, leukocyte counts and occurrence of infectious episodes were monitored on an 8 week basis. Higher 6-MP dosage was associated with higher TPMT activity (P = 0.03) and higher average leukocyte counts (P Ͻ 0.01). Eight patients (10%) carrying a TPMT mutant genotype (one homozygous and seven heterozygous) received lower 6-MP doses (average: 48 vs 65 mg/m 2 /day; P = 0.02) and had on average lower leukocyte counts (2834 vs 3398 cells/mm 3 ; P = 0.003) than patients carrying the wild-type TPMT genotype. Higher occurrence of infectious episodes graded 2 or 3 was correlated with higher 6-MP dosage (P Ͻ 0.01) but no difference was observed between TPMT mutants and TPMT wild-type patients. Patients who received 6-MP dosage above the group median (62 mg/m 2 /day) or having a TPMT activity above the group median (21.5 nmol/h/ml) had a higher percentage of 8 week periods with infectious episodes requiring treatment (34% vs 17% and 33% vs 19%, respectively) than those with 6-MP dose or TPMT activity below the group median (P Ͻ 0.01). In the last 25 patients enrolled in the study, steady-state erythrocyte thioguanine nucleotide (TGN) concentrations were associated with lower leukocyte counts (P = 0.01) but not with a higher occurrence of infectious episodes. In contrast, higher steady-state erythrocyte methylmercaptopurine nucleotide (MeMPN) concentrations were associated with higher 6-MP dosage (P Ͻ 0.01) and higher occurrence of infectious episodes (P Ͻ 0.001). In conclusion, during maintenance therapy of ALL, children with higher TPMT activity receive a higher 6-MP dosage and may have infectious episodes caused by metabolism of 6-MP into methylmercaptopurine nucleotides. Leukemia (2001Leukemia ( ) 15, 1706Leukemia ( -1712 
Introduction
The common treatment of acute lymphoblastic leukemia (ALL) is based on induction remission therapy followed by intensification and maintenance therapy 1 which consists of administration of daily 6-mercaptopurine (6-MP) with weekly methotrexate.
In vivo, the thiopurine pro-drug 6-MP, is metabolized by three competing pathways. The anabolic pathway is metabolism of 6-MP by hypoxanthine guanine phosphorybosyl transferase into thioinosine monophosphate that is subsequently metabolized into 6-thioguanine nucleotides (6- TGN) incorporated into DNA. 2, 3 Alternatively, mercaptopurine is catabolized into thiouric acid by xanthine oxidase (formation of thiouric acid) and into inactive methylmercaptopurine by thiopurine methyltransferase (TPMT; E.C: 2.1.1.67). TPMT is a cytosolic enzyme subject to genetic polymorphism. 4, 5 According to the trimodal distribution of TPMT activity in red cells, approximately 89% of Caucasians are homozygous for the high activity allele (wild type), 11% are heterozygous and about one subject in 300 inherits TPMT deficiency as an autosomal recessive trait. 4 Red blood cells (RBC) are convenient cells to study the thiopurine methyltransferase polymorphism and the intracellular metabolism of mercaptopurine. RBC TPMT activity has been demonstrated to correlate with the TPMT activity measured in various cells or organs (lymphocytes, 6 lymphoblasts, 7 (kidney, 8 liver 9 ), and RBC 6-thioguanine nucleotide concentrations are proposed for the monitoring of 6-MP during maintenance of ALL. Individuals inheriting a TPMT deficiency or patients heterozygous at the TPMT locus exhibit hematological intolerance of standard doses of mercaptopurine by a mechanism involving the accumulation of thioguanine nucleotides. [10] [11] [12] [13] However, the human thiopurine methyltransferase gene is now well characterized, and simple RFLP PCR can easily detect mutations responsible for the TPMT deficiency. 14, 15 On the other hand, little is known about the potential effects of mercaptopurine among patients exhibiting high TPMT activities. Studies by Lennard and coworkers 11 have shown that patients with high RBC TPMT activity accumulate lower active TGN concentrations; thus, these individuals have the potential to be undertreated with standard dosages of MP and are therefore more subject to relapse.
The present study was conducted during maintenance therapy of a group of children receiving methotrexate and 6-MP for the treatment of ALL. We investigated the relationship between TPMT pharmacogenetics and the pharmacological properties of mercaptopurine with management of treated patients by dose administration, leukocyte counts and infectious episode side-effects.
Materials and methods

Patients, treatment and study design
Children with ALL were enrolled at the time of diagnosis in the European chemotherapy protocol 58881 approved by an institutional review committee for clinical trials. The ethic committee of Paris Bichat-Claude Bernard approved the INSERM protocol 95020 allowing additional blood sampling for pharmacogenetic studies. The parents of our patients signed written informed consents. After 27 weeks of induction/consolidation therapy (described in detail elsewhere 16 ), maintenance therapy started. This consisted of daily 6-mercaptopurine (started at the standard dose of 50 mg/m 2 orally) and weekly methotrexate (20 mg/m 2 orally). The total duration of the planned maintenance treatment was 72 weeks (nine 8 week periods). Mercaptopurine dosage was adapted to maintain leukocyte count within the range of 2000 to 3000 cells/mm 3 . 6-MP dose was increased by 25% if two consecutive leukocyte counts at 2 weeks interval were above 4000 cells/mm 3 , and reduced by 25% if the leukocyte count reached values below 1500 cells/mm 3 . All patients received trimethoprime-sulfamethoxazole for prophylaxis against Pneumocystis carinii.
For each patient, the cumulative 6-MP dose (expressed in mg) administered orally for 8 consecutive weeks (ie 8 week period) was determined sequentially during the entire maintenance period and concomitantly with the occurrence of infections and leukocyte counts. Leukocyte counts were determined each week or every 2 weeks. The infection episodes were graded according to the following World Health Organization Toxicity Grading: grade 0 (absence of infection), grade 1 (minor infection requiring no treatment), grade 2 (moderate infection requiring treatment), grade 3 (major infection requiring treatment and hospitalization) or grade 4 (major infection with hypotension). If more than one infectious episode occurred within an 8 week period, the highest grade was assigned to the period. If an infectious episode occurred at the end an 8 week period and continued at the beginning of the following 8 week period, the infectious episode was only assigned to the first 8 week period. In all cases the toxicity grading was determined by the Pediatric Oncology Center. TPMT activity and thiopurine nucleotide concentrations were measured during follow-up visits after at least 4 consecutive weeks of unchanged 6-MP dosage (steady state). RBC TPMT activities were excluded from the analysis if the patients had received a blood transfusion in the 6 weeks preceding blood sampling.
RBC TPMT activity
Blood sample preparation and incubation conditions were similar to those previously described by Jacqz-Aigrain et al 17 and Médard et al. 18 Briefly, the amount of methyl 6-MP formed during incubation of erythrocyte lysates in the presence of 6-MP and S-adenosylmethionine (as the methyl donor) was measured by HPLC. Results were expressed as nmol of methyl 6-MP formed per hour and per milliliter of packed red blood cells. The intra-assay and inter-assay coefficients of variation over the concentration range were less than 10%. A quality control lysate was included in each assay run. Mean within day TPMT activity was 13.0 nmol/h/ml (coefficient of variation: 2.6%, n = 5). Mean between days TPMT activity was 13.6 nmol/h/ml (coefficient of variation: 5.2%, n = 8).
TPMT genotypes
Total genomic DNA was isolated from peripheral blood leukocytes using a conventional chloroform/phenol extraction procedure. The mutations in exon 5 (G238C), exon 7 (G460A) and exon 10 (A719G) were detected by RFLP-PCR assays, as reported previously. 15 The homozygote TPMT wild-type allele, was called TPMT*1, alleles presenting the G238C mutation were called TPMT*2, alleles presenting the A719G mutation were called TPMT*3C and the detection of both Leukemia G460A and A719G mutations were presumed to be combined on the same alleles (TPMT*3A).
Erythrocyte thiopurine nucleotides concentration
Red blood cell preparation and liquid chromatographic conditions were similar to the procedure described previously. 19 Intra-and inter-day coefficients of variation were less than 10% for both 6-thioguanine (6-TGN) and methylmercaptopurine (Me6MPN) nucleotides, respectively. Results are expressed as pmol/8 × 10
8 red blood cells.
Analysis of the study
For each sequential period of 8 weeks, the 6-MP dosage (mg/m 2 /day) administered to each patient was calculated by dividing the cumulative dose received (in mg) during the period by the body surface area determined at the start of each period and by the number of days (56 days).
Similarly, the mean white blood cell count within each 8 week period was calculated using all measurements collected. Subsequently, we calculated the average 6-MP dosage (mg/m 2 /day) and average leukocyte counts recovered during the entire maintenance therapy using the values calculated during the time periods (N) the patient was followed. The percentage of 8 week periods per patient having a mean white blood cell counts within a range of 2000 to 3000 cells/mm 3 was also calculated. Because the grading system used could be dependent upon the perceived need of the physician for antibiotics and or hospitalization, for each patient we determined the percentage of 8 week periods without occurrence of infectious episode by dividing the number of periods where no infections occurred (grade 0) over the total number of periods the patient was followed. Also, the percentage of 8 week periods with infectious episodes graded 2 or more was calculated.
Statistical analysis was performed with StatView and SAS software (SAS Institute, Cary, NC, USA). For each patient, the average 6-MP dose, average leukocyte counts, percentage of periods with maintenance of leukocyte count within the range of 2000 to 3000 cells/mm 3 (%), percentage of 8 week periods with infectious episodes graded 2 or 3 or percentage of periods without infections were calculated as described above and used as individual values in all subsequent analyses. Averages were compared by the non-parametric MannWhitney test or Wilcoxon test and frequencies by the Fisher exact test. The correlations between quantitative variables were evaluated with Spearman rank tests. Linear multivariate regression models were applied to adjust for potential cofounders. All significance levels reported were two-sided and set at P Ͻ 0.05.
Results
Patient treatment and pharmacological parameters
Between August 1990 and February 1998, 78 children (47 boys and 31 girls) aged 1 to 17 years (5.5 ( 3.1; average ± s.d.) and weighing from 6 to 66 kg (19.4 ± 1.04; average ± s.d.) at the time of diagnosis were included. All patients had received at least 5 months of maintenance therapy and 55 patients (70%) had completed the treatment at the time of the analysis.
The median duration of the maintenance period for the whole group of patients was 16.8 months (range 5.6-20.5).
A total of 6308 week periods (median of nine per patient) were recorded, 3353 leukocyte counts were measured (median of 45 per patient), and 198 RBC TPMT activities were determined (median of two per patient). For each patient, the average values for 6-MP dosage, the weekly methotrexate, TPMT activity, leukocyte count and percentage of 8 week periods with successful maintenance of leukocyte count within the range of 2000 to 3000 cells/mm 3 were calculated. The infectious episodes occurred in a total of 306 8 week periods in which 47% (n = 143) were graded 1, 43% (n = 132) were graded 2, and 10% (n = 31) were graded 3. No grade 4 infectious episodes occurred. The percentage of 8 week periods without occurrence of infectious episodes or with infectious episodes graded у2 (requiring treatment) was calculated for each patient. Results are summarized in Table 1 .
TPMT genotypes were determined in 75/78 patients. The RBC TPMT activity in the three patients with no DNA available ranged from 25.3 to 27.9 nmol/h/ml and they were considered homozygous wild type. Under these conditions, 70 patients (89.7%) were homozygous wild type, seven patients (9%) were heterozygous (TPMT*1/*2: n = 2, TPMT*1/*3A: n = 4, TPMT*1/*3C: n = 1) and one patient (1.2%) was homozygous mutant (TPMT*3C/*3C). The RBC TPMT activity of patients carrying point mutations at the TPMT locus was significantly lower than that of patients having a wild-type TPMT genotype (average ± s.d.: 10.7 ± 5.0 vs 22.0 ± 5.6; P Ͻ 0.0001). The TPMT activity measured in the patient having the homozygous mutant genotype (TPMT*3C/*3C) was 3.2 nmol/h/ml.
A total of 41 RBC thiopurine nucleotide concentrations were determined in the last 25 patients included in the trial (average of 1.6 measurement per patient). The 6-MP dose administered during the 4 weeks prior to blood sampling was not different from the average 6-MP dose administered during the entire maintenance period. Therefore, 6-TGN and MeMPN concentrations were considered at steady state. 
Relationship between mercaptopurine dosage, TPMT activity/genotype and leukocyte counts
In a univariate analysis, higher average mercaptopurine dose correlated with higher average leukocyte counts (r = 0.52; P Ͻ 0.0001), higher TPMT activity (r = 0.24; P = 0.03) and higher TPMT activity correlated with higher average leukocyte counts (r = 0.31; P = 0.006) (Figure 1) . In a multivariate linear regression analysis for leukocyte counts with 6-MP and TPMT activity as covariates, only 6-MP dosage remained significant (P Ͻ 0.0001).
Patients carrying a TPMT mutant genotype (heterozygous and homozygous mutant) received a lower mercaptopurine dose (P = 0.02) and had lower average leukocyte counts than patients having the wild-type TPMT genotype (P = 0.02 and P = 0.003, respectively) ( Figure 2) .
Children who received mercaptopurine doses above the group median (62 mg/m 2 /day) presented significantly lower percentage periods with successful maintenance of leukocyte counts in the range 2000 to 3000 cells/mm 3 than patients who received mercaptopurine doses below the group median (average ± s.d.: 47.9 v± 18.7% vs 65.4 ± 17.6%; P Ͻ 0.001). Similarly, children having TPMT activity above the group median (21.5 nmol/h/ml) had significantly lower percentage periods with successful maintenance of leukocyte counts in the range of 2000 to 3000 cells/mm 3 than patients with TPMT activity below the group median (average ± s.d.: 50.2 ± 19.4% vs 63.0 ± 18.6%; P = 0.002).
Relationship between mercaptopurine dose, TPMT activity/genotype and infectious episodes
The percentage of 8 week periods with infectious episodes graded у2 did not vary significantly over the maintenance period (P = 0.21; Figure 3 ). Methotrexate dose administered was not associated with the percentage of 8 week periods with infectious episodes graded у2 (P = 0.23), or with the percentage of 8 week periods with no infectious episodes (P = 0.80).
When comparing patients carrying the TPMT mutant genotype and patients having the wild-type TPMT genotype, no significant difference in the percentage of periods with no infectious episodes (average ± s.d.: 52.1 ± 23.2% vs 50.3 ± 24.6%; P = 0.78), or in the percentage of periods with infectious episodes graded у2 (average ± s.d.: 22.0 ± 21.9% vs 26.0 ± 20.0%; P = 0.56) was observed. The patients carrying the TPMT homozygous mutant genotype had 41.3% periods with infectious episodes graded у2 and 29% periods with no infectious episodes.
Patients having received 6-MP dosage above group median (62 mg/m 2 /day) had a significantly lower percentage of 8 week periods with no infections (P = 0.03), and conversely, a twofold higher percentage of 8 week periods with infectious episodes graded у2 (P = 0.0005) than those having received 6-MP dosage below the group median. Similarly, patients having TPMT activity above the group median (21.5 nmol/h/ml) had a significantly lower percentage of 8 week periods with no infections (P = 0.003) and a 1.7-fold higher occurrence of 8 week periods with infectious episodes graded у2
Figure 1
Relationship between average 6-MP dosage and average leukocyte counts (a), average 6-MP dosage and TPMT activity (b); average leukocyte counts and TPMT activity (c). Each point corresponds to the average value of repeated measurements determined during the maintenance in individual patients (ie average mercaptopurine dosage, average white blood cell count). (᭹) corresponds to patients carrying mutations at the TPMT locus. Spearman correlation coefficients (r) with P value are given for each panel. The arrow points to the patient homozygous mutant.
(P = 0.002) than those having TPMT activity below the group median. Results are summarized in Figure 4 .
In a univariate analysis, higher occurrence of infections episodes graded у2 correlated with higher mercaptopurine doses administered (r = 0.40; P = 0.001), higher white blood cell counts (r = 0.36; P = 0.01) and higher TPMT activity (r = 0.30;
Leukemia
Figure 2
Comparison of average mercaptopurine dosage administered (a), average leukocyte count (b), between TPMT mutant patients and patients having a wild-type genotype. Bars represent the average ± s.e.m. P values are given (Mann-Whitney test). P = 0.007). However, in a multivariate linear regression analysis including mercaptopurine dosage, TPMT activity and leukocyte counts, only mercaptopurine dosage was associated with the percentage of periods with infectious episodes graded у2 (P = 0.03).
Steady-state erythrocyte thiopurine nucleotide concentrations
In the last 25 patients included in the trial, 6-TGN and MeMPN concentrations were measured in RBC. 6-TGN concentrations measured in three patients carrying TPMT mutations (two were heterozygous and one homozygous) were 3.3-fold higher (median: 1031 pmol/8 × 10 8 cells, range 918-1334) than those measured in the 22 patients having a Percentage of 8 week periods with infectious episodes graded у2 (2 or 3) over the maintenance periods in the 78 patients. Bars represent the average with confidence interval at 95% at each 8 week period.
wild-type genotype (median: 307 pmol/8 × 10 8 cells, range 173-559) (P Ͻ 0.001). In contrast, the 22 patients having a wild-type TPMT genotype had significantly higher MeMPN concentrations (median: 6137 pmol/8 × 10 8 cells, range 637-19 682) than the three patients carrying TPMT mutations (median: 307 pmol/8 × 10 8 cells, range 20-336). Higher TPMT activity correlated significantly with lower 6-TGN concentrations (r = −0.48; P = 0.01) but not with higher MeMPN concentrations. 6-TGN concentrations were not associated with 6-MP dosage, percentage of periods with infectious episodes graded 2 or 3, or percentage of periods without infectious episodes. However, higher steady-state 6-TGN concentrations correlated significantly with lower average leucocyte counts (r = −0.56; P = 0.003) (Figure 5a ). Steady-state MeMPN concentrations correlated with higher 6-MP dosage (r = 0.64; P = 0.0004), higher percentage of periods with infectious episodes graded у2 (r = 0.50; P = 0.01) and lower percentage of periods without infectious episodes (r = −0.56; P = 0.003) (Figure 5b) . Finally, in a multivariate linear regression analysis including 6-MP dosage and MeMPN concentrations, higher MeMPN concentrations remained associated with the occurrence of infectious episodes (P Ͻ 0.01).
Discussion
6-MP is an antileukemic agent administered during the maintenance phase of childhood ALL. 1 The objective is to maintain the complete remission obtained after several courses of intensive chemotherapy for approximately 6 months (induction phase). The inter-individual variation in the antileukemic effect of mercaptopurine is in part related to variations of the thiopurine methyltransferase activity. 11, 12, 20 It is generally accepted that patients with high TPMT activity require an increase of their mercaptopurine dosage to overcome mercaptopurine catabolism and obtain an antileukemic effect, 12, 21 and that patients with low TPMT activity or a TPMT mutant genotype require dosage reduction to avoid severe hematological toxicity due to the extensive formation of cytotoxic thioguanine nucleotides. 12, 22 We prospectively followed 78 children during the maintenance therapy of ALL and investigated the relationship Comparison of percentage of 8 week periods with no infectious episodes (a) or with infectious episodes graded у2 (b) in patients who received an average 6-MP dose below or above the median group (62 mg/m 2 /day) or, had erythrocyte TPMT activity below or above the median group (21.5 nmol/h/ml). Bars represent the average with confidence interval at 95%. P values are given. The below median groups include the eight patients having a TPMT mutant genotype (one homozygous mutant and seven heterozygous) plus 31 patients having a wild-type TPMT genotype; the above median groups include 39 patients having a TPMT wild-type genotype.
between the thiopurine methyltransferase locus and response to mercaptopurine treatment. In our study, TPMT activities were highly variable and, as expected, patients with higher TPMT activity received higher doses of 6-MP. According to the therapeutic protocol, the mercaptopurine dose was increased to achieve the antileukemic effect. Unexpectedly, we observed a positive relationship between higher TPMT activity, higher mercaptopurine doses and higher leukocyte counts. The influence of TPMT genotype was further investigated. Children carrying a TPMT mutant genotype received a lower mercaptopurine dose and had lower leukocyte counts than patients with a wild-type genotype. In addition, patients with a TPMT mutant genotype had higher steady-state red blood cell thioguanine nucleotide concentrations, which were associated with lower leukocyte counts. This is in accordance with previous reports, demonstrating greater leukopenia sec-
Figure 5
Relationships between (a) steady-state erythrocyte thioguanine nucleotides and average leukocyte counts, (b) steady-state erythrocyte methylmercaptopurine nucleotide concentrations and percentage of periods with infectious episodes graded 2 or 3. Spearman correlation coefficients (r) with P values are given for each panel. Lines correspond to the linear regression. The arrow points to the patient TPMT homozygous mutant.
ondary to the formation of thioguanine nucleotides, 11, 12, 20 and with the concept that prospective identification of TPMT mutations may help to decrease excessive hematological toxicity in individuals with low TPMT activity. 22 Factors associated with white blood cell counts were further investigated in a multivariate analysis including TPMT activity and 6-MP. Only 6-MP remained significant, showing that, 6-MP dose remains the major determinant of the leukocyte counts during maintenance therapy. This suggests that, despite high 6-MP dosage, patients with high leukocyte counts may not have received 6-MP doses high enough to maintain the white blood cell counts in the range of 2000-3000/mm 3 . A similar result was recently reported by Schiemegelow and Bretton-Meyer 23 during continuation therapy of ALL. In the present study, higher doses of mercaptopurine and higher TPMT activity were also associated with a higher occurrence of infectious episodes. However, there was no association between the occurrence of infectious episodes and Leukemia TPMT genotype as demonstrated previously. 12 Here again, in a multivariate analysis including 6-MP dosage, TPMT activity, and leukocyte counts, only 6-MP remained significantly associated with the occurrence of infectious episodes. Therefore, 6-MP appears as the risk factor of infections during maintenance therapy in patients with ALL.
As previously stated, 6-MP is metabolized into 6-thioguanine nucleotides (6-TGN) and alternatively catabolized into inactive methylmercaptopurine by thiopurine methyltransferase. Besides mercaptopurine, TPMT also methylates thiopurine nucleotides into methylthiopurine nucleotides (ie methylmercaptopurine nucleotides). In vitro studies have shown that methylmercaptopurine nucleotides contribute to the antiproliferative properties of 6-MP, 24 probably by inhibiting phosphoribosylamidotransferase, the first enzymatic step in purine de novo synthesis. 25, 26 Clinical data have shown that TPMTdeficient patients can tolerate higher thioguanine nucleotide concentrations than patients with high TPMT, suggesting a deleterious effect of 6-methylmercaptopurine nucleotides. 10, 20 In addition, lymphocytes having high TPMT activity have greater inhibition of mitogen stimulation after mercaptopurine treatment than lymphocytes with low TPMT activity. 27 Therefore, the occurrence of infections associated with the formation of methylmercaptopurine nucleotides may be related to the inhibition of de novo purine synthesis, already reported as the mechanism of action of immunosuppressive agents such as mycophenolate. 28 Although TGN concentrations were not related to the occurrence of infectious episodes, patient having a TPMT mutant genotype may also be at high risk of infectious episodes, as the treatment induces neutropenia and myelotoxicity. This is supported by the fact that our patient with a TPMT homozygous mutant genotype had high TGN concentrations, no detectable MeMPN concentrations, and high occurrence of infectious episodes. The analysis of the type of infection was not planned in the present protocol but we speculate that infectious episodes occurring during maintenance therapy may be related to high concentrations of methylmercaptopurine nucleotides in patients having high TPMT activity or to neutropenia induced by 6-thioguanine nucleotides in patients having low TPMT activity.
In conclusion, our results suggest that during the maintenance therapy of ALL, children with high TPMT activity receiving high doses of 6-MP may be at risk of infections, probably through metabolism of 6-MP into methylmercaptopurine nucleotides.
